Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets - Merck & Co (NYSE:MRK), Oncotelic Therapeutics (OTC:OTLC)

Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging.

Related Keywords

United States ,Americans ,Oncotelic Therapeutics , ,National Cancer Institute On Unsplash ,Merck Co ,Transforming Growth Factor Beta ,National Cancer Institute ,